OCUGEN, INC. Interest Expense Nonoperating
OCUGEN, INC. (OCGN) reported Interest Expense Nonoperating of $4.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- OCUGEN, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $4.48M, a 248.33% increase year-over-year.
- OCUGEN, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $1.32M, a 5.01% increase year-over-year.
- OCUGEN, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $1.33M, a 121.63% increase year-over-year.
- OCUGEN, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $1.31M, a 4431.03% increase year-over-year.
- OCUGEN, INC. interest expense nonoperating for fiscal 2025 was $5.19M, a 654.07% increase from fiscal 2024.
- OCUGEN, INC. interest expense nonoperating for fiscal 2024 was $688.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.48M 10-Q · filed 2026-08-06 | $5.80M 10-Q · filed 2026-08-06 | $7.13M derived: sum of 3 quarters · filed 2026-08-06 | $8.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.32M 10-Q · filed 2026-05-08 | $2.65M derived: sum of 2 quarters · filed 2026-05-08 | $3.97M derived: sum of 3 quarters · filed 2026-05-08 | $5.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $2.65M derived: sum of 2 quarters · filed 2026-03-04 | $3.93M derived: sum of 3 quarters · filed 2026-08-06 | $5.19M 10-K · filed 2026-03-04 |
| 2025-09-30 | $1.31M 10-Q · filed 2025-11-05 | $2.60M derived: sum of 2 quarters · filed 2026-08-06 | $3.86M 10-Q · filed 2025-11-05 | $4.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.28M 10-Q · filed 2026-08-06 | $2.54M 10-Q · filed 2026-08-06 | $3.14M derived: sum of 3 quarters · filed 2026-08-06 | $3.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.26M 10-Q · filed 2026-05-08 | $1.86M derived: sum of 2 quarters · filed 2026-05-08 | $1.89M derived: sum of 3 quarters · filed 2026-05-08 | |
| 2024-12-31 | $601.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $630.00K derived: sum of 2 quarters · filed 2026-03-04 | $688.00K 10-K · filed 2026-03-04 | |
| 2024-09-30 | $29.00K 10-Q · filed 2025-11-05 | $87.00K 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |